Evidence map›Paper›PMID 30099860›Full record

ArticleCancer medicine2018

Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.

Wenjie Zhu, Mei Liu, Ying Fan, Fei Ma, Ningzhi Xu, Binghe Xu

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03779022 unknown statusnot on this map

MicroRNA and Relevant Biomarkers of Breast Cancer in Patients Undergoing Neoadjuvant Treatment

TypeobservationalSponsorCui YiminRan2015 to 2019Enrolled100ConditionsBreast CancerArmsmicroRNA
NCT05151224 unknown statusnot on this mapstarted 2021, after this paper: background citation

Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma

TypeobservationalSponsorAin Shams UniversityRan2021 to 2024Enrolled40ConditionsBreast CarcinomaArmsmicroRNA 21
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Observational
  6. Review
  7. Review
  8. Potential biomarkers as a predictive factor of response to primary chemotherapy in breast cancer patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  9. Review
  10. Review
  11. Interplay between LncRNAs and microRNAs in Breast Cancer.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Targeting non-coding RNAs to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenjie ZhuNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Mei LiuLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ying FanNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Fei MaNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ningzhi XuLaboratory of Cell and Molecular Biology & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Binghe XuNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0003-4195-337X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating microRNAs (miRNAs) have been indicated as predictive biomarkers in breast cancer. We aimed to explore the association of plasma miRNA dynamics with response to neoadjuvant chemotherapy (NCT) and disclose early markers for predicting sensitivity.

methodsOne hundred and nine patients with operable or locally advanced breast cancer, who participated in a prospective clinical trial and received NCT, were analyzed. Blood samples were collected before random assignment, after two cycles of chemotherapy (C2) and before surgery. Based on their clinical response, the patients were defined as chemo-sensitive or insensitive. First, baseline and preoperative samples of selected cases from both groups were screened via TaqMan miRNA array for candidate miRNAs. Afterward all the biospecimens were tested for the candidate miRNAs (miR-222, miR-20a, miR-451, miR-9, miR-34a, miR-155, and miR-145) by quantitative real-time PCR. Finally, logistic regression model was utilized to determine the predictive value of baseline/C2 expression of these miRNAs.

resultsBased on the results of microRNA profiling, seven miRNAs were selected for further validation. In the HR+/HER2- cohort (n = 51) dynamics of three miRNAs, including miR-222, miR-20a, and miR-451, were associated with chemo-sensitivity. Importantly, across all the three subtypes we consistently identified chemo-induced decrease in plasma miR-34a in the insensitive patients. Finally, baseline miR-222 overexpression (OR = 6.422, P = 0.049), C2 miR-20a up-regulation (OR = 0.144, P = 0.021) and C2 miR-451 down-regulation (OR = 8.213, P = 0.012) were predictive markers of response to NCT in HR+/HER2- breast cancer.

conclusionsWe described that dynamics of circulating miRNAs might help predict clinical response to NCT in breast cancer.

Indexed as

Biomarkers, TumorCirculating MicroRNAAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRandomized Controlled Trials as TopicROC CurveSensitivity and SpecificityBiomarkers, TumorCirculating MicroRNAbreast cancercirculating miRNAsdynamicsneoadjuvant chemotherapysensitivity

Identifiers

PMID30099860
PMCPMC6144164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.